Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | USP7 | Q93009 | 5/20 | 0.37 |
| ▸ | ESR1 | P03372 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685341 | 0.81 | GABRA1 (0.43) | ESR2USP7ESR1CNR1CNR2 | |
| SCHEMBL14675581 | 0.79 | ESR2 (0.41) | ESR2CYP19A1USP7ESR1CNR1 | |
| SCHEMBL14675564 | 0.78 | ESR2 (0.43) | ESR2CYP19A1USP7ESR1CNR1 | |
| SCHEMBL14675169 | 0.78 | USP7 (0.46) | ESR2CYP19A1USP7ESR1CNR1 | |
| SCHEMBL16193775 | 0.78 | ESR1 (0.43) | ESR2CYP19A1USP7ESR1CNR1 | |
| SCHEMBL21141749 | 0.75 | ESR1 (0.33) | USP7ESR1CNR1CNR2ALOX5 | |
| SCHEMBL16194112 | 0.75 | USP7 (0.34) | ESR2USP7ESR1CNR1CNR2 | |
| SCHEMBL16194114 | 0.75 | USP7 (0.34) | ESR2USP7ESR1CNR1CNR2 | |
| SCHEMBL16193768 | 0.75 | ESR2 (0.47) | ESR2CYP19A1USP7PDE3BPDE3A | |
| SCHEMBL28146428 | 0.72 | PTGS2 (0.45) | ESR2CYP19A1USP7ESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| EP-2739609-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017654-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ESR2 4/4885CYP19A1 11/4885USP7 1983/4885 |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ESR2 4/4885CYP19A1 11/4885USP7 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.